Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%

MT Newswires Live

Jan 22, 2025

Orthocell (ASX:OCC) is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.

It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.

The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.

It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.

The firm's shares rallied 14% in early trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505586757"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505586757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505586757?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-22 09:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505586757","market":"sg","top_or_hot":-1,"title":"Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%","media":"MT Newswires Live","content":"<html><body><p> Orthocell (ASX:OCC) is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.</p><p>It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.</p><p>The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.</p><p>It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.</p><p>The firm's shares rallied 14% in early trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell Accelerates Global Expansion for Remplir, Shares Rally 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-22 09:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Orthocell (ASX:OCC) is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.</p><p>It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.</p><p>The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.</p><p>It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.</p><p>The firm's shares rallied 14% in early trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCC.AU","symbol_name":"ORTHOCELL LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505586757","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505586757","pubTimestamp":1737508624,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell  is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.The firm's shares rallied 14% in early trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCC.AU":"ORTHOCELL LTD","XAO.AU":"标普/澳交所 普通股指数","XJO.AU":"标普/澳交所 200指数","XKO.AU":"标普/澳交所 300指数","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Orthocell加速Remplir全球扩张，股价上涨14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":0.9,"XJO.AU":0.69,"XKO.AU":0.69,"XAO.AU":0.69},"content_text":"Orthocell (ASX:OCC) is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.The firm's shares rallied 14% in early trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}